Eton Pharmaceutcials Inc ETON

$55.36 +3.38 (6.50%)

Valuation

Market cap
1,485,744,000
Revenue TTM
$79,950,000
Net income TTM
$-4,600,000
PE ratio
135.50
Forward PE
45.77
Profit margin
-5.75%
Debt to equity
0.60

Trading

Volume
749,900
Avg volume
618,220
Day's range
$52.00 – $56.00
Shares out
28,583,000
Stochastic %K
56%
Beta
0.90
Analysts
Strong Sell
Price target
$64.10

Price

Company profile

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate syn...

Show more

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
847 787 7361
Website
https://www.etonpharma.com
Address
21925 W. Field Parkway, Suite 235, Deer Park, United States

Latest news